LITHI - PHARMA
ActiveSummary
LITHI - PHARMA has been active since 1993 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €553,324 and a net result of -€223,557. Equity is growing by about 11% per year across the filed financial years. Its solvency ranks better than 53% of 1,110 sector peers (NACE 93, financial year 2025). The computed 12-month bankruptcy probability is 0.8% (low).
Articles of association
What the company does
- DurationHow long the company exists; usually unlimited, so until it is dissolved.
- Unlimited
- Name clauseThe name the company operates under according to its articles.
- LITHI-PHARMA
- Registered office clauseThe region of the registered office; it decides among other things the language of official documents.
- “Vlaamse Gewest” (deed in Dutch)
Who represents it, and how
- Board ruleHow the board is made up, meets and takes decisions.
- “Algemene vergadering kan mandaat te allen tijde zonder opgave van redenen met onmiddellijke ingang beëindigen, hoogstens zes jaar” (deed in Dutch)
- Power of attorneyA special mandate allowing someone to perform one or more acts on the company's behalf.
- One provision in the deed
Meetings and financial year
- Annual meetingWhen the shareholders meet each year, among other things to approve the annual accounts.
- Fourth Saturday of December at 14:00
Oversight and winding up
- Dissolution ruleWhen and by whom the company can be dissolved.
- “Ontbinding bij besluit algemene vergadering, zoals inzake statutenwijziging” (deed in Dutch)
- Liquidation ruleHow assets are shared after dissolution: creditors first, then shareholders.
- “Één of meer vereffenaars, ontbinding om welke reden en op welk ogenblik ook” (deed in Dutch)1 more provision on this in the deed